IQVIA Holdings Inc. $IQV Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 18.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 160,057 shares of the medical research company’s stock after buying an additional 24,854 shares during the quarter. IQVIA comprises 0.9% of Dana Investment Advisors Inc.’s holdings, making the stock its 17th largest position. Dana Investment Advisors Inc. owned 0.09% of IQVIA worth $30,401,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in IQV. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA during the 2nd quarter worth $515,772,000. Norges Bank acquired a new stake in IQVIA during the second quarter worth about $270,160,000. AQR Capital Management LLC raised its stake in IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares during the period. Laurel Wealth Advisors LLC boosted its holdings in IQVIA by 15,755.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on IQV shares. TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Morgan Stanley set a $240.00 target price on IQVIA in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday. Finally, Truist Financial reduced their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Price Performance

IQV opened at $162.08 on Tuesday. The stock’s 50-day moving average price is $216.37 and its 200 day moving average price is $208.54. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The firm has a market cap of $27.50 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.60 and a beta of 1.37. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the prior year, the firm earned $3.12 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.